Periotherapia is a drug discovery business with triple negative breast cancer as the first indication.
Periotherapia has raised $6.8M in total funding. The most recent round was Grant. The last funding was announced in May 2026.
Periotherapia's investors include Mitsubishi UFJ Capital, Osaka University Venture Capital, Chushin Venture Capital, AMED, Techno Science.
Periotherapia is headquartered in Osaka, Japan.
Periotherapia is a drug discovery business with triple negative breast cancer as the first indication.
Periotherapia is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Periotherapia — Funding & Investors." VCBacked, May 26, 2026, https://www.vcbacked.co/company/periotherapia. Accessed November 12, 2026.
VCBacked. (2026). Periotherapia — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/periotherapia
{{cite web |title=Periotherapia — Funding & Investors |url=https://www.vcbacked.co/company/periotherapia |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Periotherapia? Request a listing update